Quarterly report pursuant to Section 13 or 15(d)

Note 1 - Corporate Information (Details Textual)

v3.23.3
Note 1 - Corporate Information (Details Textual) - USD ($)
$ in Thousands
3 Months Ended 9 Months Ended
Sep. 30, 2023
Sep. 30, 2022
Sep. 30, 2023
Sep. 30, 2022
Jul. 18, 2023
Dec. 31, 2022
May 31, 2013
Reduction in Workforce, Percentage         70.00%    
Reduction in Workforce, Cost $ 6,800   $ 6,800        
Cash, Cash Equivalents, and Short-Term Investments 44,800   44,800        
Net Income (Loss) Attributable to Parent (10,752) $ (9,736) (19,959) $ (25,175)      
Retained Earnings (Accumulated Deficit) $ (310,380)   $ (310,380)     $ (290,421)  
Pieris Pharmaceuticals GmbH [Member]              
Business Acquisition, Percentage of Voting Interests Acquired             100.00%